| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
103.36(B) |
| Last
Volume: |
682,467 |
Avg
Vol: |
1,619,368 |
| 52
Week Range: |
$323.57 - $446.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
67,740 |
152,280 |
258,193 |
599,211 |
| Total Sell Value |
$28,555,052 |
$61,805,647 |
$99,413,137 |
$200,212,570 |
| Total People Sold |
8 |
12 |
15 |
18 |
| Total Sell Transactions |
28 |
41 |
68 |
132 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sachs Bruce I |
Director |
– • – |
2023-07-17 |
4 |
OE |
$127.54 |
$1,434,825 |
D/D |
11,250 |
51,250 |
|
- |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2023-07-17 |
4 |
AS |
$355.00 |
$2,778,940 |
D/D |
(7,828) |
118,906 |
|
-1% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2023-05-30 |
4 |
AS |
$329.82 |
$27,045 |
D/D |
(82) |
56,556 |
|
11% |
|
| Ambrose Kristen |
SVP & Chief Accounting Officer |
• – – |
2023-05-30 |
4 |
AS |
$329.82 |
$95,318 |
D/D |
(289) |
6,838 |
|
11% |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2023-05-08 |
4 |
AS |
$349.00 |
$392,625 |
D/D |
(1,125) |
35,387 |
|
1% |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2023-05-08 |
4 |
AS |
$350.00 |
$997,500 |
D/D |
(2,850) |
32,038 |
|
1% |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2023-05-05 |
4 |
AS |
$349.38 |
$307,262 |
D/D |
(879) |
36,512 |
|
0% |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2023-05-05 |
4 |
AS |
$350.03 |
$147,713 |
D/D |
(422) |
34,888 |
|
0% |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2023-05-03 |
4 |
AS |
$349.22 |
$1,578,301 |
D/D |
(4,508) |
37,391 |
|
0% |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2023-05-03 |
4 |
AS |
$350.44 |
$975,418 |
D/D |
(2,781) |
35,310 |
|
0% |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2023-05-02 |
4 |
AS |
$349.48 |
$2,256,761 |
D/D |
(6,450) |
41,899 |
|
0% |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2023-05-02 |
4 |
AS |
$350.32 |
$568,768 |
D/D |
(1,622) |
38,091 |
|
0% |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2023-05-02 |
4 |
AS |
$345.93 |
$202,004 |
D/D |
(580) |
4,628 |
|
0% |
|
| Carney Lloyd |
Director |
– • – |
2023-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,168 |
5,318 |
|
- |
|
| Upadhyay Suketu |
Director |
– • – |
2023-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,168 |
2,726 |
|
- |
|
| Mckenzie Diana |
Director |
– • – |
2023-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,168 |
2,603 |
|
- |
|
| Mckenzie Diana |
Director |
– • – |
2023-05-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,449) |
1,435 |
|
- |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2023-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,168 |
5,208 |
|
- |
|
| Garber Alan M |
Director |
– • – |
2023-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
584 |
6,474 |
|
- |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2023-04-27 |
4 |
AS |
$338.69 |
$1,124,726 |
D/D |
(3,317) |
126,652 |
|
1% |
|
| Sachs Bruce I |
Director |
– • – |
2023-04-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,210 |
40,000 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2023-04-12 |
4 |
AS |
$325.70 |
$2,472,164 |
D/D |
(7,567) |
39,713 |
|
7% |
|
| Sachs Bruce I |
Director |
– • – |
2023-04-12 |
4 |
AS |
$325.65 |
$6,959,422 |
D/D |
(21,300) |
41,210 |
|
7% |
|
| Sachs Bruce I |
Director |
– • – |
2023-04-12 |
4 |
OE |
$72.14 |
$1,536,582 |
D/D |
21,300 |
62,510 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2023-04-04 |
4 |
AS |
$314.22 |
$164,854 |
D/D |
(522) |
47,280 |
|
11% |
|
3258 Records found
|
|
Page 6 of 131 |
|
|
0.22 (0.06%) 
